Effect of 2.5 Years of Rasagiline Therapy on Progression of Cognitive Biomarkers Assessed by MRI in Parkinson's Disease.

NCT02278588 · clinicaltrials.gov ↗

COMPLETED

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Parkinson's Disease

Interventions

DRUG: Rasagiline

Sponsor

State University of New York at Buffalo